Education
About Us
Working with TipRanks
Follow Us
Pharming Group Nv (PHAR)
:PHAR
PHAR Stock Chart & Stats
$14.21
-$0.05(-0.51%)
At close: 4:00 PM EST
$14.21
-$0.05(-0.51%)
Day’s Range― - ―
52-Week Range$7.31 - $17.08
Previous CloseN/A
Volume181.00
Average Volume (3M)13.39K
Market Cap
$933.06M
Enterprise Value$744.24M
Total Cash (Recent Filing)$128.73M
Total Debt (Recent Filing)$128.33M
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Nov 06, 2025EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding68,514,760
10 Day Avg. Volume10,966
30 Day Avg. Volume13,388
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue2.18
Enterprise Value/Gross Profit2.44
Enterprise Value/Ebitda24.47
Forecast
1Y Price Target
$39.00Price Target Upside174.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
FDA ApprovalThe FDA's sNDA approval for leniolisib as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS) highlights a significant advancement for Pharming Group Nv.
Financial PerformancePharming announced 2Q25 financial results, posting EPS of $0.006 compared to an estimate of ($0.025), with total revenue for the quarter at $93.2 million vs. an estimate of $83.26 million.
Market ExpansionExpanding leniolisib into the pediatric population addresses an unmet medical need and represents a substantial market opportunity.
Bears Say
Pharming Group News
PHAR FAQ
What was Pharming Group Nv’s price range in the past 12 months?
Pharming Group Nv lowest stock price was $7.31 and its highest was $17.08 in the past 12 months.
What is Pharming Group Nv’s market cap?
Pharming Group Nv’s market cap is $933.06M.
When is Pharming Group Nv’s upcoming earnings report date?
Pharming Group Nv’s upcoming earnings report date is Nov 06, 2025 which is in 8 days.
How were Pharming Group Nv’s earnings last quarter?
Pharming Group Nv released its earnings results on Jul 31, 2025. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of -$0.105 by $0.165.
Is Pharming Group Nv overvalued?
According to Wall Street analysts Pharming Group Nv’s price is currently Undervalued.
Does Pharming Group Nv pay dividends?
Pharming Group Nv does not currently pay dividends.
What is Pharming Group Nv’s EPS estimate?
Pharming Group Nv’s EPS estimate is <0.01.
How many shares outstanding does Pharming Group Nv have?
Pharming Group Nv has 68,514,760 shares outstanding.
What happened to Pharming Group Nv’s price movement after its last earnings report?
Pharming Group Nv reported an EPS of $0.06 in its last earnings report, beating expectations of -$0.105. Following the earnings report the stock price went up 10.109%.
Which hedge fund is a major shareholder of Pharming Group Nv?
Currently, no hedge funds are holding shares in PHAR
Pharming Group Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$39.00 (174.45% Upside)
$39.00 (174.45% Upside)
Blogger Sentiment
Bullish
PHAR Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.21%
12-Months-Change
Fundamentals
Return on Equity
-3.40%
Trailing 12-Months
Asset Growth
7.29%
Trailing 12-Months
Company Description
Pharming Group Nv
Pharming Group N.V. is a biopharmaceutical company focused on the development of innovative therapies for rare diseases, particularly those related to protein deficiencies. The company specializes in the production of recombinant human proteins using its proprietary technologies, with a core focus on its lead product, Ruconest, a treatment for acute attacks of hereditary angioedema. Pharming operates primarily in the biotechnology and pharmaceutical sectors, and its mission is to address unmet medical needs through its advanced therapeutic solutions.
PHAR Company Deck
PHAR Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong positive sentiment due to significant revenue growth, a turnaround in operating profits, and expansion of the pipeline. However, there are some concerns about inventory impacts on revenue and potential market disruptions.View all PHAR earnings summariesPHAR Stock 12 Month Forecast
Average Price Target
$39.00
▲(174.45% Upside)
Technical Analysis
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Praxis Precision Medicines
―
ARS Pharmaceuticals
―
Prime Medicine, Inc.
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
0.08% Other Institutional Investors
99.92% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---